Nutshell Biotech (Shanghai) Co. Ltd. has discovered fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer.

Suzhou Zion Pharma Technology Co. Ltd. has divulged serine-protein kinase ATM (ataxia telangiectasia mutated) inhibitors reported to be useful for the treatment of cancer.

Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.

Medshine Discovery Inc. has presented furan fused ring-substituted glutarimides as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to androgen receptor-targeting moiety reported to be useful for the treatment of prostate cancer.

Shenzhen Forward Pharmaceutical Co. Ltd. has divulged estrogen receptor α (ERα) antagonists and/or degradation inducers reported to be useful for the treatment of cancer.

Allorion Therapeutics Co. Ltd. has patented nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.

Sironax Ltd. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of ulcerative colitis, Crohn's disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis, Alzheimer's disease and viral infections.

Shire Human Genetic Therapies Inc. has discovered new plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema and diabetic macular edema.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized orexin OX2 receptor antagonists reported to be useful for the treatment of major depression and insomnia.

Idorsia Pharmaceuticals Ltd. has described cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.